Clinical Trial Update: A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) pilot study evaluating dose-escalating RICE chemotherapy plus bortezomib for relapsed or primary refractory aggressive B-cell non-Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Lymphoma, B-Cell | EARLY_Phase 1 | Status: TERMINATED